Literature DB >> 7908318

Magnetic resonance imaging of human melanoma xenografts in vivo: proton spin-lattice and spin-spin relaxation times versus fractional tumour water content and fraction of necrotic tumour tissue.

E K Rofstad1, E Steinsland, O Kaalhus, Y B Chang, B Høvik, H Lyng.   

Abstract

Proton nuclear magnetic resonance (1H-nmr) imaging is used routinely in clinical oncology to provide macroscopic anatomical information, whereas its potential to provide physiological information about tumours is not well explored. To evaluate the potential usefulness of 1H-nmr imaging in the prediction of tumour treatment resistance caused by unfavourable microenvironmental conditions, possible correlations between proton spin-lattice and spin-spin relaxation times (T1 and T2) and physiological parameters of the tumour microenvironment were investigated. Tumours from six human melanoma xenograft lines were included in the study. 1H-nmr imaging was performed at 1.5 T using spin-echo pulse sequences. T1- and T2-distributions were generated from the images. Fractional tumour water content and the fraction of necrotic tumour tissue were measured immediately after 1H-nmr imaging. Significant correlations across tumour lines were found for T1 and T2 versus fractional tumour water content (p < 0.001) as well as for T1 and T2 versus fraction of necrotic tumour tissue (p < 0.05). Tumours with high fractional water contents had high values of T1 and T2, probably caused by free water in the tumour interstitium. Fractional water content is correlated to interstitial fluid pressure in tumours, high interstitial fluid pressure being indicative of high vascular resistance. Tumours with high fractional water contents are thus expected to show regions with radiobiologically hypoxic cells as well as poor intravascular and interstitial transport of many therapeutic agents. T1 and T2 decreased with increasing fraction of necrotic tumour tissue, perhaps because complexed paramagnetic ions were released during development of necrosis. Viable tumour cells adjacent to necrotic regions are usually chronically hypoxic. Tumours with high fractions of necrotic tissue are thus expected to contain significant proportions of radiobiologically hypoxic cells. Consequently, quantitative 1H-nmr imaging has the potential to be developed as an efficient clinical tool in prediction of tumour treatment resistance caused by hypoxia and/or transport barriers for therapeutic agents. However, much work remains to be done before this potential can be adequately evaluated. One problem is that high fractional tumour water contents result in longer T1 and T2 whereas high fractions of necrotic tumour tissue result in shorter T1 and T2; i.e. the two parameters which are indicative of treatment resistance contribute in opposite directions. Another problem is that the correlations for T1 and T2 versus fraction of necrotic tumour tissue are not particularly strong.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7908318     DOI: 10.1080/09553009414550451

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  11 in total

1.  Spin-spin relaxation times in myocardial hypertrophy induced by endocrine agents in rat.

Authors:  C Burtea; R Gatina; G Stoian; M Mardare; I F Dumitru; C T Dragomir
Journal:  MAGMA       Date:  1998-12       Impact factor: 2.310

2.  Proton relaxation times and interstitial fluid pressure in human melanoma xenografts.

Authors:  H Lyng; I Tufto; A Skretting; E K Rofstad
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 3.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

4.  Tumor vascularity assessed by magnetic resonance imaging and intravital microscopy imaging.

Authors:  Jon-Vidar Gaustad; Kjetil G Brurberg; Trude G Simonsen; Camilla S Mollatt; Einar K Rofstad
Journal:  Neoplasia       Date:  2008-04       Impact factor: 5.715

5.  Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.

Authors:  Murali K Ravoori; Masato Nishimura; Sheela P Singh; Chunhua Lu; Lin Han; Brian P Hobbs; Sunila Pradeep; Hyun J Choi; James A Bankson; Anil K Sood; Vikas Kundra
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

6.  Evaluation of pancreatic tumor development in KPC mice using multi-parametric MRI.

Authors:  Ravneet Vohra; Joshua Park; Yak-Nam Wang; Kayla Gravelle; Stella Whang; Joo-Ha Hwang; Donghoon Lee
Journal:  Cancer Imaging       Date:  2018-11-08       Impact factor: 3.909

7.  Detection of necrosis in human tumour xenografts by proton magnetic resonance imaging.

Authors:  I Jakobsen; O Kaalhus; H Lyng; E K Rofstad
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

8.  Tumour T1 changes in vivo are highly predictive of response to chemotherapy and reflect the number of viable tumour cells--a preclinical MR study in mice.

Authors:  Claudia Weidensteiner; Peter R Allegrini; Melanie Sticker-Jantscheff; Vincent Romanet; Stephane Ferretti; Paul M J McSheehy
Journal:  BMC Cancer       Date:  2014-02-14       Impact factor: 4.430

9.  Renal carcinoma CD105-/CD44- cells display stem-like properties in vitro and form aggressive tumors in vivo.

Authors:  M Fiedorowicz; M I Khan; D Strzemecki; J Orzeł; M Wełniak-Kamińska; A Sobiborowicz; M Wieteska; Z Rogulski; L Cheda; W Wargocka-Matuszewska; K Kilian; C Szczylik; A M Czarnecka
Journal:  Sci Rep       Date:  2020-03-25       Impact factor: 4.379

10.  Intravital microscopy of tumor vessel morphology and function using a standard fluorescence microscope.

Authors:  Jon-Vidar Gaustad; Trude G Simonsen; Lise Mari K Hansem; Einar K Rofstad
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-19       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.